International Task Force on Relapsed Ewing Sarcoma

A global collaboration of scientists, clinicians, industry partners, and patient advocates working to build the framework that future relapsed Ewing sarcoma trials will be designed around.

37

Members

10

Countries

20+

Institutions

The Gap We Are Addressing

Why this Task Force exists

This global group of scientists, clinicians, industry partners, and patient advocates is focused on a critical gap in the field: the lack of an adequate framework to guide the development of new clinical trials for patients with relapsed Ewing sarcoma. Without such a framework, trials risk being sub-optimally designed, undermining the ability to effectively evaluate and advance promising new agents.

In June 2026, ESI hosted a two-day in-person convening of the Task Force to advance these discussions and arrive at formal global consensus. The outcomes will be submitted for publication as a manuscript to serve as a definitive resource guiding the standardization, design, and implementation of future clinical trials for Ewing sarcoma — helping to ensure that new agents are evaluated as effectively and efficiently as possible.

ESI International Task Force · June 1–3, 2026

37 members across 10 countries — clinicians, scientists, statisticians, advocates & survivors

37

Members

10

Countries

20+

Institutions

Physician / scientist Biostatistician Patient advocate Survivor advocate ESI / industry / facilitation Virtual

Clinicians & Scientists

MD PhD Kelly Bailey Mayo Clinic

MD PhD Pablo Berlanga Gustave Roussy

MD Emily Blauel Children’s Hosp. CO

MD Rashmi Chugh Univ. of Michigan

MD Brian Crompton Dana-Farber

MD Uta Dirksen Univ. Duisburg-Essen

MD MS Steve DuBois Dana-Farber

MD PhD Nathalie Gaspar Gustave Roussy

MD Julia Glade Bender Mem. Sloan Kettering

MD PhD Patrick Grohar Univ. of Michigan

PhD Nicola Hughes Univ. of Leeds

MD Katie Janeway Dana-Farber

MD Antonio Juan Ribelles Hosp. La Fe, Spain

MD Ted Laetsch Children’s Hosp. CHOP

MD Roberto Luksch NCI Milan

MD Martin McCabe Univ. Manchester

MD Hans Merks Princess Maxima, NL

MD Karsten Nysom Copenhagen Univ. Hosp.

MD Katie Offer Hackensack Univ. MC

MD Marianne Phillips Perth Children’s Hosp.

MD Andreas Ranft Essen Univ. Hosp.

MD Damon Reed Mem. Sloan Kettering

MD Elyssa Rubin Children’s Hosp. OC

MD Dave Shulman Dana-Farber

MD Sandra Strauss UCL . EEC chair

MD Claudia Valverde Vall d’Hebron / VHIO

Industry Katie Thornton Johnson & Johnson

Biostatisticians

PhD Natalie DelRocco Children’s Oncology Group

MSc Piers Gaunt Univ. of Birmingham

Patient Advocates & Survivors

Advocate Carol Basso EEC . In memory of Anna

Survivor Alex Berlin 10 yr NED

Advocate Nicole Croft EEC . Bone Cancer Research Trust

Advocate Lorna Day Sam Day Foundation

Advocate Lisa Landers Charlie Landers Foundation

Survivor Fiorella Marchelli UK

Advocate Andy Westwood EEC . rEECur trial group

Operations & Facilitation

Director Pei Pei Ma Ewing Sarcoma Institute

Facilitator Cherie Gardiner Evolution